Omnicell, Inc. (NASDAQ:OMCL) Chairman Randall A. Lipps sold 9,482 shares of the firm’s stock in a transaction on Tuesday, December 18th. The stock was sold at an average price of $63.89, for a total value of $605,804.98. Following the completion of the transaction, the chairman now owns 165,025 shares of the company’s stock, valued at approximately $10,543,447.25. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
NASDAQ OMCL opened at $63.75 on Wednesday. The stock has a market cap of $2.52 billion, a price-to-earnings ratio of 354.17, a P/E/G ratio of 3.80 and a beta of 0.99. Omnicell, Inc. has a fifty-two week low of $39.75 and a fifty-two week high of $79.48. The company has a quick ratio of 1.32, a current ratio of 1.78 and a debt-to-equity ratio of 0.27.
Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, October 25th. The company reported $0.49 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.40 by $0.09. The business had revenue of $204.27 million during the quarter, compared to analyst estimates of $203.48 million. Omnicell had a return on equity of 7.91% and a net margin of 6.11%. Analysts forecast that Omnicell, Inc. will post 1.42 EPS for the current year.
A number of equities analysts recently issued reports on OMCL shares. Craig Hallum raised their target price on Omnicell from $65.00 to $80.00 and gave the stock a “buy” rating in a research note on Monday, September 17th. Cantor Fitzgerald raised their target price on Omnicell from $63.00 to $70.00 and gave the stock an “overweight” rating in a research note on Friday, October 26th. raised their target price on Omnicell from $59.00 to $71.00 and gave the stock an “in-line” rating in a research note on Monday, October 22nd. Benchmark raised their target price on Omnicell from $66.00 to $79.00 and gave the stock a “buy” rating in a research note on Friday, October 5th. Finally, BidaskClub lowered Omnicell from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 4th. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $73.75.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.
Featured Article: Call Option
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.